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1. INTRODUCTION {#dom13981-sec-0005}
===============

Metformin monotherapy frequently proves inadequate for glycaemic control in patients with type 2 diabetes (T2D), necessitating additional glucose‐lowering agents.[1](#dom13981-bib-0001){ref-type="ref"}, [2](#dom13981-bib-0002){ref-type="ref"}, [3](#dom13981-bib-0003){ref-type="ref"}, [4](#dom13981-bib-0004){ref-type="ref"} A patient‐centric approach is recommended to select an appropriate add‐on therapy.[5](#dom13981-bib-0005){ref-type="ref"} Injectable insulin may not appeal to the patient and is associated with body weight (BW) gain and an increased risk of hypoglycaemia. The ideal oral add‐on antihyperglycaemic agent should have long‐term efficacy, attain glycated haemoglobin A~1c~ (HbA1c) targets without hypoglycaemia through complementary mechanisms of action,[5](#dom13981-bib-0005){ref-type="ref"}, [6](#dom13981-bib-0006){ref-type="ref"} and achieve BW reduction or neutrality.

Studies have reported that the sodium‐glucose cotransporter‐2 inhibitor (SGLT‐2i) dapagliflozin (DAPA) plus the dipeptidyl peptidase‐4 inhibitor (DPP‐4i) saxagliptin (SAXA) in combination with metformin provides superior HbA1c reductions versus either agent added to metformin alone, with a lower risk of hypoglycaemia and BW gain.[6](#dom13981-bib-0006){ref-type="ref"}, [7](#dom13981-bib-0007){ref-type="ref"}, [8](#dom13981-bib-0008){ref-type="ref"}, [9](#dom13981-bib-0009){ref-type="ref"}, [10](#dom13981-bib-0010){ref-type="ref"}, [11](#dom13981-bib-0011){ref-type="ref"}, [12](#dom13981-bib-0012){ref-type="ref"} The risk of genital infection is lower in treatment regimens with the combination of DAPA + SAXA than DAPA monotherapy.[13](#dom13981-bib-0013){ref-type="ref"} However, validation is needed to determine the long‐term efficacy of DAPA + SAXA versus injectable insulin as an add‐on to metformin therapy in patients with T2D.

This Phase 3 study is part of a clinical programme supporting the development of a fixed‐dose combination (FDC) of DAPA 10 mg and SAXA 5 mg for T2D management. In an earlier 24‐week randomized trial, in patients with T2D that were inadequately controlled on metformin with or without sulphonylurea, co‐administration with DAPA + SAXA was non‐inferior to co‐administration with insulin glargine (INS) in achieving HbA1c reductions and reducing BW gain and hypoglycaemia.[14](#dom13981-bib-0014){ref-type="ref"} In the 28‐week extension, we compared the efficacy, tolerability and safety of DAPA + SAXA versus INS over 52 weeks with respect to HbA1c, BW and glycaemic control in patients with T2D that were inadequately controlled on metformin with or without sulphonylurea.

2. MATERIALS AND METHODS {#dom13981-sec-0006}
========================

2.1. Study design {#dom13981-sec-0007}
-----------------

This is a 52‐week, multicentre (112 centres across 11 countries), randomized, open‐label, two‐arm, parallel‐group, Phase 3b study ([ClinicalTrials.gov](http://clinicaltrials.gov) identifier: NCT02551874; Figure [1](#dom13981-fig-0001){ref-type="fig"}).

![Study design. \*Additional visits only for patients participating in the CGM substudy. ^\#^Increase in the daily dose of insulin (based on FPG and SMBG values) at weeks 8 and 12 was at the discretion of the investigator. The goal was to reach an acceptable and stable dose by week 12. After week 12, patients with confirmed central laboratory‐measured FPG values \>200 mg/dL (11.1 mmol/L) were eligible for open‐label rescue medication (including further uptitration of daily dose of insulin). DAPA + SAXA, DAPA (10 mg/day) + SAXA (5 mg/day) + metformin ± SU; INS, INS (100 U/mL/day) + metformin ± SU. Abbreviations: CGM, continuous glucose monitoring; DAPA, dapagliflozin; FPG, fasting plasma glucose; INS, insulin glargine; SAXA, saxagliptin; SMBG, self‐monitored blood glucose; SU, sulphonylurea](DOM-22-957-g001){#dom13981-fig-0001}

The study was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference on Harmonisation, and approved by the relevant institutional review boards or independent ethics committees. All persons gave informed consent for both the short‐ and long‐term study periods before study inclusion.

Adult (age ≥18 years) male or female patients with T2D and inadequate glycaemic control (HbA1c ≥8% to ≤12%) receiving stable metformin therapy (≥1500 mg/day) with or without sulphonylurea (≥50% of maximal dose) for at least 8 weeks before screening were eligible. Study participants had body mass index (BMI) ≤45.0 kg/m^2^ at screening and baseline fasting plasma glucose (FPG) ≤270 mg/dL. Major exclusion criteria included type 1 diabetes, maturity‐onset diabetes of the young, secondary diabetes or diabetes insipidus, and a history of diabetic ketoacidosis or of renal impairment (creatinine clearance \<60 mL/min and serum creatinine ≥1.5 mg/dL in men or ≥1.4 mg/dL in women). Participants were randomized 1:1 using an interactive voice response system stratified by sulphonylurea use with background metformin treatment to receive either DAPA + SAXA or INS for 24 weeks with a long‐term extension (Figure [2](#dom13981-fig-0002){ref-type="fig"}).

![Patient disposition. \*Number of patients receiving metformin + SU = 166, number of patients receiving metformin -- SU = 158. ^\#^Number of patients receiving metformin + SU = 165, number of patients receiving metformin -- SU = 154. DAPA + SAXA, DAPA (10 mg/day) + SAXA (5 mg/day) + metformin ± SU. INS, INS (100 U/mL/day) + metformin ± SU. Abbreviations: DAPA, dapagliflozin; INS, insulin glargine; *N*, total number of patients in the group; *n*, number of patients analysed; SAXA, saxagliptin; SU, sulphonylurea](DOM-22-957-g002){#dom13981-fig-0002}

DAPA 10 mg/day (BMS‐512148; BMS, New Brunswick, New Jersey) and SAXA 5 mg/day (BMS‐477118; BMS, Mount Vernon, Indiana) were administered orally as tablets, and 100 U/mL INS (Sanofi, Quebec, Canada) was administered as a subcutaneous injection. All patients continued to receive their previous dose regimen of metformin with or without sulphonylurea throughout the study. Insulin dose was self‐titrated by patients in 2‐U increments every 3 days, starting from 0.2 U/kg BW on day 1 until week 8, based on daily glucose monitoring and an FPG target of ≤100 mg/dL. Uptitration of the insulin dose was withheld in case of any unexplained hypoglycaemic events (FPG ≤70 mg/dL) in the preceding 3 days. The dose was increased at week 8 and/or week 12 at the investigator\'s discretion and was maintained stably, thereafter, to facilitate comparison of HbA1c with the main 24‐week study, unless there were safety concerns or rescue medication requirement. Patients with FPG ≥200 mg/dL after week 12 and up to and including week 24 and patients with HbA1c \>8% after week 24 and up to and including week 52 were eligible for open‐label rescue medication. Insulin was recommended as the first‐line rescue therapy. Additionally, patients meeting rescue criteria received open‐label antihyperglycaemic rescue medication, initiated at the lowest starting dose and titrated according to the product label in the applicable country.

Patients completing the short‐term treatment period continued into the long‐term extension period, receiving the same open‐label study medication that they were randomized to on day 1 along with metformin with or without sulphonylurea. All patients performed a six‐point self‐monitored blood glucose (SMBG) on any three non‐consecutive days during the long‐term period and continued to record their fasting SMBG twice daily, study medication dosing, hypoglycaemic episodes and mealtimes. The investigator reviewed patients' diary entries between visits to identify any hypoglycaemic events, including symptoms with or without SMBG ≤70 mg/dL.

2.2. Efficacy endpoints {#dom13981-sec-0008}
-----------------------

Measurements of efficacy at week 52 included mean change in HbA1c and BW from baseline and achieving an optimal glycaemic response (HbA1c \<7.0%) without hypoglycaemia. Assessments comprised central laboratory measurements of HbA1c and SMBG values during treatment to assess hypoglycaemia. BW was measured in kilograms or pounds using the same digital precision scales at each visit. Other endpoints included the proportion of patients requiring rescue medication or discontinuing due to lack of glycaemic control and change from baseline in the average postprandial glucose values measured by six‐point SMBG profiles over 52 weeks. Patient‐reported outcomes (PROs) were assessed using self‐administered PRO questionnaires (Phase V® Health Outcomes Information System Diabetes Module) comprising validated generic and diabetes‐specific modules of treatment satisfaction, quality of life and barriers to medication adherence.

2.3. Safety endpoints {#dom13981-sec-0009}
---------------------

Safety analyses were conducted using the treated patients' data set (including data after rescue), defined as all patients who received at least one dose of the study medication. Safety and tolerability were evaluated based on the analyses of adverse events (AEs), vital signs, physical examinations, electrocardiograms, hypoglycaemia and clinical laboratory evaluations. AEs were classified by primary system organ class and the preferred term according to MedDRA20.0 and were sorted by decreasing frequency. All AEs (serious and non‐serious), including all hypoglycaemic events, were summarized by treatment group, where applicable. No formal comparisons were made between treatments. Two analyses‐related deaths were reported during the study in the DAPA + SAXA group, one each in the short‐ and long‐term periods. Serious AEs (SAEs), including hypoglycaemic events, were described in narratives regardless of the investigator\'s assessment of causality. All AEs that led to discontinuation were listed.

Separate summaries were provided for AEs of special interest (AESI) and included hypoglycaemic events, urinary tract infections, renal impairment, genital infections, hepatic injury, bone fractures, hypersensitivity reactions, volume depletion and cardiac failure. The AESI and serious AESI with an onset from day 1 of the short‐term treatment period through 4 and 30 days after the last dose date in the short‐ and long‐term treatment periods, respectively, occurred during the combined short‐ and long‐term periods.

2.4. Statistical analyses {#dom13981-sec-0010}
-------------------------

Statistical analyses were performed using SAS® version 9.4 (SAS Institute, Cary, North Carolina) according to the statistical analysis plan. The analysis of efficacy endpoints was performed using a direct likelihood longitudinal repeated‐measures analysis, including the fixed categorical effects of treatment, week, randomization stratification factor (metformin with or without sulphonylurea background medication), and treatment‐by‐week interaction and the continuous fixed covariates of baseline measurement and baseline measurement‐by‐week interaction.[15](#dom13981-bib-0015){ref-type="ref"}, [16](#dom13981-bib-0016){ref-type="ref"} The intent‐to‐treat population comprised randomized subjects who received at least one dose of study medication (primary efficacy data set). Efficacy analyses were performed using the data collected before initiation of the rescue treatment or treatment discontinuation.

Kaplan--Meier plots of time‐to‐event variables were generated for the treatment groups. The 95% confidence interval (CI) was restricted to 0 or 1 if the estimated value of the lower bound was \<0 or the upper bound was \>1, respectively. An upper bound CI of \<0.3% implied non‐inferiority of DAPA + SAXA versus INS group. No formal statistical testing was performed for safety endpoints; only summary statistics were provided.[14](#dom13981-bib-0014){ref-type="ref"}

The data underlying the findings described in this study may be obtained in accordance with AstraZeneca\'s data sharing policy described at <https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure>.

3. RESULTS {#dom13981-sec-0011}
==========

3.1. Patients {#dom13981-sec-0012}
-------------

In total, 1163 patients with T2D were enrolled from October 20, 2015 to October 19, 2016, of which 707 patients entered the lead‐in treatment phase. Overall, 650 patients were randomized: 324 received DAPA + SAXA treatment and 326 received INS. The mean total daily insulin dose at week 52 was 37.9 U. Seven patients from the INS group (1.1%) were excluded because they did not receive at least one dose of open‐label treatment. Of the 643 patients who received randomized treatment, 600 (93.3%) entered the long‐term treatment period. Most participants who received treatment (579; 96.2%) completed the study (Figure [2](#dom13981-fig-0002){ref-type="fig"}). Overall, 3.8% of patients discontinued study treatment during the 52‐week, open‐label treatment period; 3.7% in the DAPA + SAXA group and 3.9% in the INS group before week 52. Five patients (0.9%), two (0.7%) in the DAPA + SAXA group and three (1.1%) in the INS group, were lost to follow‐up. Four patients (0.7%), three (1.0%) from the DAPA + SAXA group and one (0.4%) from the INS group, withdrew from the study due to "other" reasons (personal emergency, incorrect randomization, significant cognitive impairment and inability to attend study visits). Four patients (0.7%), two (0.7%) in each treatment group, requested discontinuation of treatment and withdrew from the study. In total, 121 patients (18.8%) had at least one relevant protocol deviation. The most common deviation leading to complete exclusion was overall non‐compliance (i.e., patients who took \<80% or \>120% of their prescribed dose of study medication during the short‐term treatment period).

Patient demographics and baseline characteristics were well balanced between groups (Table [1](#dom13981-tbl-0001){ref-type="table"}). Most patients were white (80.4%); 54% were men. The mean ± standard deviation (SD) age was 55.5 ± 9.6 years and time since T2D diagnosis was 9.4 ± 6.3 years. The mean BW of patients was 89.6 ± 18.1 kg and the mean BMI was 32.2 ± 5.3 kg/m^2^. Most patients (92.5%) were overweight (BMI ≥25 kg/m^2^), while 62.4% of patients were obese (BMI ≥30 kg/m^2^). The mean ± SD estimated glomerular filtration rate was similar between the groups (94.6 ± 23.7 mL/min/1.73 m^2^ in the DAPA + SAXA group and 97.3 ± 21.8 mL/min/1.73 m^2^ in the INS group).

###### 

Patient demographics and baseline characteristics

  Characteristic                                                DAPA + SAXA (*N* = 324)   INS (*N* = 319)
  ------------------------------------------------------------- ------------------------- -----------------
  Age, years, mean ± SD                                         55.7 ± 9.52               55.3 ± 9.63
  Sex, *n* (%)                                                                            
  Male                                                          176 (54.3)                171 (53.6)
  Female                                                        148 (45.7)                148 (46.4)
  Race, *n* (%)                                                                           
  White                                                         263 (81.2)                254 (79.6)
  African American                                              28 (8.6)                  35 (11.0)
  Asian                                                         12 (3.7)                  12 (3.8)
  American Indian                                               12 (3.7)                  6 (1.9)
  Native Hawaiian                                               0 (0.0)                   1 (0.3)
  Other                                                         9 (2.8)                   11 (3.4)
  Duration of T2D, years, mean ± SD                             9.6 ± 6.5                 9.3 ± 6.2
  HbA1c, %, mean ± SD                                           9.0 ± 1.0                 9.1 ± 1.1
  BW, kg, mean ± SD                                             89.8 ± 17.7               89.4 ± 18.4
  BMI, kg/m^2^, mean ± SD                                       32.5 ± 5.3                32.0 ± 5.4
  FPG, mg/dL, mean ± SD                                         189.5 ± 55.5              188.6 ± 53.8
  eGFR, mL/min/1.73 m^2^, mean ± SD                             94.6 ± 23.7               97.3 ± 21.8
  Background therapies[a](#dom13981-note-0005){ref-type="fn"}                             
  Allowed concomitant medication, *n* (%)                       288 (88.9)                279 (87.5)
  HMG CoA reductase inhibitors                                  139 (42.9)                127 (39.8)
  ACE inhibitors, plain                                         111 (34.3)                121 (37.9)
  Platelet aggregation inhibitors, excluding heparin            77 (23.8)                 83 (26.0)
  β‐blockers, selective                                         61 (18.8)                 65 (20.4)
  Angiotensin II antagonists, plain                             44 (13.6)                 43 (13.5)
  Propionic acid derivatives                                    41 (12.7)                 39 (12.2)
  Proton pump inhibitors                                        39 (12.0)                 41 (12.9)
  Anilides                                                      44 (13.6)                 35 (11.0)

**Abbreviations:** ACE, angiotensin‐converting enzyme; BMI, body mass index; BW, body weight; DAPA, dapagliflozin; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; HMG CoA, 3‐hydroxy‐3‐methylglutaryl coenzyme A; INS, insulin glargine; *N*, total number of patients in the group; *n*, number of patients analysed; SAXA, saxagliptin; SD, standard deviation; SU, sulphonylurea; T2D, type 2 diabetes.

DAPA + SAXA, DAPA (10 mg/day) + SAXA (5 mg/day) + metformin ± SU; INS, INS (100 U/mL/day) + metformin ± SU. Values are mean ± SD or *n* (%) unless otherwise stated.

Treated patients' data. Percentages are based on the number of patients in the randomized data set.

Among the 643 patients in the randomized data set, 166 (51.2%) in the DAPA + SAXA group and 165 (51.7%) in the INS group received sulphonylurea at randomization, and all patients received metformin background therapy, regardless of treatment group or sulphonylurea use. The most common specific disease history terms (those reported in \>10% of patients overall) were T2D (100%), hypertension (65.8%), hyperlipidaemia (41.7%), history of obesity (38.3%), dyslipidaemia (30.2%) and diabetic neuropathy (18.7%). Five patients (0.8%) had a history of amputation (one in the DAPA + SAXA group and four in the INS group). The use of allowed concomitant medications, reported for 288 patients (88.9%) in the DAPA + SAXA group and 279 patients (87.5%) in the INS group, was well balanced between the groups (Table [1](#dom13981-tbl-0001){ref-type="table"} and [Table S1](#dom13981-supitem-0001){ref-type="supplementary-material"}; see [Supporting Information](#dom13981-supitem-0001){ref-type="supplementary-material"}). The most frequently used allowed concomitant medications were statins (41.4%), plain angiotensin‐converting enzyme inhibitors (36.1%), platelet aggregation inhibitors, excluding heparin (24.9%) and selective β‐blockers (19.6%). Both groups had a low incidence of disallowed concomitant medication usage, reported for nine patients (2.8%) in the DAPA + SAXA group and five patients (1.6%) in the INS group ([Table S1](#dom13981-supitem-0001){ref-type="supplementary-material"}; see [Supporting Information](#dom13981-supitem-0001){ref-type="supplementary-material"}). Treatment compliance was high and balanced between the groups.

3.2. Efficacy {#dom13981-sec-0013}
-------------

All efficacy analyses of the long‐term treatment period were exploratory and reported for the randomized patient data set. Mean HbA1c decreased from baseline to week 52 in both groups (Figure [3](#dom13981-fig-0003){ref-type="fig"}A). The adjusted least squares (LS) mean change (95% CI) in HbA1c was −1.5% (−1.6%, −1.4%) for the DAPA + SAXA group and − 1.3% (−1.4%, −1.1%) for the INS group; the LS mean difference (95% CI) between the groups was −0.25% (−0.4%, −0.1%; *P* = 0.009).

![A, Percentage change from baseline in HbA1c over 52 weeks. Week 0 refers to the baseline value. Baseline is defined as patients in the randomized patient data set with non‐missing baseline assessment and at least one post‐baseline assessment. HbA1c assessments, collected after initiation of rescue treatment or collected more than 8 days after the last dose in the short‐term plus long‐term open‐label treatment period, were excluded from the analysis. *n*, number of patients. B, Change in BW from baseline over 52 weeks. Week 0 refers to the baseline value. Baseline is defined as patients in the randomized patient data set with non‐missing baseline assessment and at least one post‐baseline assessment. BW assessments, collected after initiation of rescue treatment or collected more than 8 days after the last dose in the short‐term plus long‐term open‐label treatment period, were excluded from the analysis. *n*, number of patients. C, Proportion of patients achieving adjusted optimal glycaemic response (HbA1c \<7%) without hypoglycaemia at week 52. Percentages calculated on the randomized subject data set. \*Patients with unknown status at week 52 and patients given rescue medication before week 52 were treated as non‐responders for the endpoint. ^\#^Based on the logistic regression method with adjustment for baseline HbA1c and randomization stratification factor (background medication of metformin ± SU). ^†^Based on the logistic regression method with adjustment for baseline HbA1c (background medication of metformin ± SU and treatment by randomization stratification factor interaction). *n*, number of patients with an event of optimal glycaemic response at week 52. D, Proportion of patients requiring rescue or discontinuation due to lack of glycaemic control at week 52. Percentages calculated on the randomized subject data set. \*Patients with unknown status at week 52 and patients given rescue medication before week 52 were treated as non‐responders for the endpoint. ^\#^Based on the logistic regression method with adjustment for baseline HbA1c and randomization stratification factor (background medication of metformin ± SU). *n*, number of patients needing rescue or discontinuation at week 52. DAPA + SAXA, DAPA (10 mg/day) + SAXA (5 mg/day) + metformin ± SU; INS, titrated INS (100 U/mL/day) + metformin ± SU. Abbreviations: BW, body weight; CI, confidence interval; DAPA, dapagliflozin; HbA1c, glycated haemoglobin; INS, insulin glargine; *N*, total number of patients in the treatment group; OR, odds ratio; SAXA, saxagliptin; SU, sulphonylurea](DOM-22-957-g003){#dom13981-fig-0003}

The mean reduction in BW from baseline to week 52 in the DAPA + SAXA group differed significantly from that in the INS group (Figure [3](#dom13981-fig-0003){ref-type="fig"}B). At week 52, the adjusted LS mean (95% CI) BW decreased with DAPA + SAXA by −1.8 kg (−2.4, −1.3), while increasing by +2.8 kg (2.2, 3.3) in the INS group. The LS mean difference (95% CI) between the two groups was −4.6 kg (−5.3, −3.8; *P* \<0.001).

Overall, the proportion of patients \[adjusted percentage (95% CI)\] achieving an optimal glycaemic response (HbA1c \<7%) at week 52 was 29.8% (24.8%, 35.3%) in the DAPA + SAXA group and 24.0% (19.5%, 29.3%) in the INS group, regardless of background sulphonylurea treatment. Optimal glycaemic response without hypoglycaemia was achieved in 57 patients (17.6%) in the DAPA + SAXA group \[41 patients (25.9%) without background sulphonylurea group, 16 patients (9.6%) with background sulphonylurea\] and 29 patients (9.1%) in the INS group \[17 patients (11%) without background sulphonylurea group, 12 patients (7.3%) with background sulphonylurea\] at week 52. The adjusted percentage (95% CI) of patients achieving an optimal glycaemic response without hypoglycaemia was 15.2% (11.6%, 19.8%) and 7.2% (4.8%, 10.6%) with DAPA + SAXA and INS, respectively \[odds ratio (OR): 2.3; 95% CI: 1.4, 3.8\] (Figure [3](#dom13981-fig-0003){ref-type="fig"}C). Confirmed hypoglycaemia was found in a smaller proportion of patients in the DAPA + SAXA group (28.7%) compared with the INS group (46.1%) (OR: 0.4; 95% CI: 0.3, 0.6), regardless of background sulphonylurea therapy.

Overall, 174 patients required rescue medication or discontinued the study due to lack of glycaemic control: 77 (23.8%) in the DAPA + SAXA group and 97 (30.4%) in the INS group at week 52. The adjusted percentage (95% CI) of patients requiring rescue medication or discontinuation at week 52 was 21.0% (16.7%, 26.1%) and 27.7% (22.8%, 33.3%) in the DAPA + SAXA and INS groups, respectively (OR: 0.7; 95% CI: 0.5, 1.0; Figure [3](#dom13981-fig-0003){ref-type="fig"}D).

Changes from baseline in average and postprandial glucose values were measured by a six‐point SMBG at week 52, which were similar across the groups \[average SMBG level, LS mean (95% CI): DAPA + SAXA, −43.6 mg/dL (−48.2, −38.9); INS, −39.3 mg/dL (−44.2, −34.6)\], with the DAPA + SAXA treatment causing greater decrease in mean postprandial SMBG level \[DAPA + SAXA, −48.1 mg/dL (−53.2, −42.9)\]; INS \[−40.2 mg/dL (−45.7, −34.8)\]. Decreases in FPG were evident at all time points beginning at week 1, with a mean change (95% CI) from baseline of −49.9 mg/dL (−56.9, −42.9) and −56.0 mg/dL (−65.0, −47.1) in the DAPA + SAXA and INS groups, respectively, at week 52 ([Figure S1](#dom13981-supitem-0001){ref-type="supplementary-material"}; see [Supporting Information](#dom13981-supitem-0001){ref-type="supplementary-material"}).

The mean overall satisfaction with treatment increased in both groups between baseline and week 52 ([Table S2](#dom13981-supitem-0001){ref-type="supplementary-material"}; see [Supporting Information](#dom13981-supitem-0001){ref-type="supplementary-material"}). The LS mean change \[standard error (SE)\] in the DAPA + SAXA group \[9.4 (0.7)\] was significantly greater (*P* = 0.006) than the INS group \[6.0 (0.7)\]. Treatment group comparisons of the regimen acceptance score, a subdomain of treatment satisfaction, also showed significantly better results with DAPA + SAXA at week 52 (LS mean difference: 4.2; *P* \< 0.001). The short‐ and long‐term results were similar, indicating a significantly higher level of treatment satisfaction in patients receiving DAPA + SAXA than those on INS.

3.3. Safety {#dom13981-sec-0014}
-----------

The mean ± SD duration exposure, regardless of rescue medication use, was similar between treatment groups (DAPA + SAXA, 338.5 ± 81.9 days; INS, 330.1 ± 93.4). Most patients in both treatment groups had a cumulative exposure of \>270 days (\>38 weeks). At least one AE was reported by 209 patients (64.5%) in the DAPA + SAXA group and 217 (68.0%) in the INS group (Table [2](#dom13981-tbl-0002){ref-type="table"}). AEs considered by the investigator to be treatment‐related were more common in the DAPA + SAXA group (11.1%) versus the INS group (4.7%). Two patients (0.6%) in the DAPA + SAXA group died during the study, one in the short‐term period (respiratory failure) and one in the long‐term period (pulmonary oedema); both deaths were not considered related to treatment. Hypoglycaemic events were fewer in the DAPA + SAXA group versus the INS group before rescue medication use. Neither group had any hypoglycaemic event leading to study drug discontinuation. The most frequently reported SAE was coronary artery disease (0.9% in the DAPA + SAXA group; 0.3% in the INS group), followed by congestive cardiac failure (0.6% in the DAPA + SAXA; 0.3% in the INS group) and acute coronary syndrome (0.3% in the DAPA + SAXA group; 0.6% in the INS group). No other SAE was reported for more than one patient. Diabetic ketoacidosis was reported by one patient in the INS group. There were no amputations in either treatment arm. No SAE was considered by the investigator to be related to treatment.

###### 

AEs (incident rate ≥5% for both AEs and SAEs) in any category during the 52‐week treatment period, regardless of rescue

  AE category                                                                  DAPA + SAXA (*N* = 324) *n* [a](#dom13981-note-0008){ref-type="fn"} (%)   INS (*N* = 319) *n* [a](#dom13981-note-0008){ref-type="fn"} (%)
  ---------------------------------------------------------------------------- ------------------------------------------------------------------------- -----------------------------------------------------------------
  At least one AE                                                              209 (64.5)                                                                217 (68.0)
  Most common AEs                                                                                                                                        
  Viral upper respiratory tract infection                                      25 (7.7)                                                                  19 (6.0)
  Upper respiratory tract infection                                            17 (5.2)                                                                  23 (7.2)
  Urinary tract infection                                                      16 (4.9)                                                                  11 (3.4)
  Back pain                                                                    15 (4.6)                                                                  13 (4.1)
  Headache                                                                     12 (3.7)                                                                  22 (6.9)
  Dizziness                                                                    8 (2.5)                                                                   1 (0.3)
  Diarrhoea                                                                    7 (2.2)                                                                   11 (3.4)
  Nausea                                                                       5 (1.5)                                                                   8 (2.5)
  Hypertension                                                                 1 (0.3)                                                                   15 (4.7)
  AEs of special interest                                                                                                                                
  Hypoglycaemic events                                                         100 (30.9)                                                                153 (48.0)
  Severe hypoglycaemia                                                         0 (0.0)                                                                   3 (0.9)
  Urinary tract infections                                                     20 (6.2)                                                                  16 (5.0)
  Renal impairment/failure                                                     9 (2.8)                                                                   3 (0.9)
  Blood creatinine increased                                                   5 (1.5)                                                                   1 (0.3)
  GFR decreased                                                                5 (1.5)                                                                   1 (0.3)
  Creatinine renal clearance decreased                                         1 (0.3)                                                                   0 (0.0)
  Genital infections                                                           16 (4.9)                                                                  2 (0.6)
  Cardiac failure                                                              5 (1.5)                                                                   7 (2.2)
  Acute congestive heart failure                                               2 (0.6)                                                                   0 (0.0)
  Pulmonary oedema                                                             1 (0.3)                                                                   0 (0.0)
  Bone fractures                                                               3 (0.9)                                                                   4 (1.3)
  Hypersensitivity reactions                                                   14 (4.3)                                                                  11 (3.4)
  Hepatic injury                                                               7 (2.2)                                                                   10 (3.1)
  Volume depletion (hypotension, dehydration, hypovolaemia)                    6 (1.9)                                                                   2 (0.6)
  Hypotension                                                                  4 (1.2)                                                                   1 (0.3)
  BP decreased                                                                 1 (0.3)                                                                   0 (0.0)
  Syncope                                                                      1 (0.3)                                                                   1 (0.3)
  Any AE leading to death                                                      2 (0.6)                                                                   0 (0.0)
  AE leading to discontinuation of IP[b](#dom13981-note-0009){ref-type="fn"}   8 (2.5)                                                                   2 (0.6)
  Investigations                                                               5 (1.5)                                                                   0 (0.0)
  Blood creatinine increased                                                   2 (0.6)                                                                   0 (0.0)
  GFR decreased                                                                2 (0.6)                                                                   0 (0.0)
  Blood potassium abnormal                                                     1 (0.3)                                                                   0 (0.0)
  Respiratory disorders                                                        2 (0.6)                                                                   0 (0.0)
  COPD                                                                         1 (0.3)                                                                   0 (0.0)
  Pulmonary oedema                                                             1 (0.3)                                                                   0 (0.0)
  Respiratory failure                                                          1 (0.3)                                                                   0 (0.0)
  Vascular disorders                                                           1 (0.3)                                                                   0 (0.0)
  Hypotension                                                                  1 (0.3)                                                                   0 (0.0)
  Nervous system disorders                                                     0 (0.0)                                                                   1 (0.3)
  Ischaemic stroke                                                             0 (0.0)                                                                   1 (0.3)
  Neoplasms (benign, malignant, unspecified)                                   0 (0.0)                                                                   1 (0.3)
  Colon cancer                                                                 0 (0.0)                                                                   1 (0.3)
  Treatment‐emergent AEs[c](#dom13981-note-0010){ref-type="fn"}                36 (11.1)                                                                 15 (4.7)
  Infections and infestations                                                  15 (4.6)                                                                  2 (0.6)
  Urinary tract infection                                                      5 (1.5)                                                                   2 (0.6)
  Vulvovaginal mycotic infection                                               3 (0.9)                                                                   0 (0.0)
  Gastrointestinal disorders                                                   5 (1.5)                                                                   3 (0.9)
  Nervous system disorders                                                     3 (0.9)                                                                   1 (0.3
  Dizziness                                                                    3 (0.9)                                                                   0 (0.0)
  Cardiac disorders                                                            1 (0.3)                                                                   0 (0.0)
  Palpitations                                                                 1 (0.3)                                                                   0 (0.0)
  Metabolism and nutrition disorders                                           2 (0.6)                                                                   1 (0.3)
  Vascular disorders                                                           1 (0.3)                                                                   0 (0.0)
  At least one SAE                                                             20 (6.2)                                                                  13 (4.1)
  Most common SAEs[d](#dom13981-note-0011){ref-type="fn"}                                                                                                
  Cardiac disorders                                                            7 (2.2)                                                                   4 (1.3)
  Coronary artery disease                                                      3 (0.9)                                                                   1 (0.3)
  Cardiac failure congestive                                                   2 (0.6)                                                                   1 (0.3)
  Acute coronary syndrome                                                      1 (0.3)                                                                   2 (0.6)
  Acute myocardial infarction                                                  1 (0.3)                                                                   0 (0.0)
  Neoplasms (benign, malignant, unspecified)                                   4 (1.2)                                                                   1 (0.3)
  Injury, poisoning, procedural complications                                  4 (1.2)                                                                   1 (0.3)
  Respiratory disorders                                                        3 (0.9)                                                                   0 (0.0)
  COPD                                                                         1 (0.3)                                                                   0 (0.0)
  Pulmonary embolism                                                           1 (0.3)                                                                   0 (0.0)
  Renal and urinary disorders                                                  2 (0.6)                                                                   1 (0.3)
  Haematuria                                                                   1 (0.3)                                                                   0 (0.0)
  Acute kidney injury                                                          0 (0.0)                                                                   1 (0.3)
  Gastrointestinal disorders                                                   1 (0.3)                                                                   0 (0.0)
  Metabolism and nutrition disorders                                           0 (0.0)                                                                   1 (0.3)
  Diabetic ketoacidosis                                                        0 (0.0)                                                                   1 (0.3)
  SAE leading to discontinuation of IP                                         2 (0.6)                                                                   1 (0.3)

Abbreviations: AE, adverse event; BP, blood pressure; COPD, chronic obstructive pulmonary disease; DAPA, dapagliflozin; GFR, glomerular filtration rate; INS, titrated insulin glargine; IP, investigational product (study drug); *N*, total number of patients in the group; *n*, number of patients analysed; PT, preferred term; SAE, serious adverse event; SAXA, saxagliptin; SOC, system organ class; SU, sulphonylurea.

DAPA + SAXA, DAPA (10 mg/day) + SAXA (5 mg/day) + metformin ± SU; INS, INS (100 U/mL/day) + metformin ± SU.

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories. The deaths were considered non‐treatment‐related.

Number (%) of patients with an AE leading to discontinuation of IP, sorted by international order for SOC and by decreasing frequency of PT within each SOC for DAPA + SAXA. Patients with multiple AEs leading to discontinuation were counted once for each SOC/PT.

Causally related to any study medication, as assessed by the investigator.

SAEs by system organ class and preferred term during the 52‐week open‐label treatment period, regardless of rescue.

4. DISCUSSION {#dom13981-sec-0015}
=============

Guidelines recommend combination therapies with glucose‐lowering agents to manage the progressive nature of T2D when metformin monotherapy fails to achieve or sustain glycaemic control.[5](#dom13981-bib-0005){ref-type="ref"} To the best of our knowledge, this study is the first to evaluate the efficacy and safety of an FDC of DAPA + SAXA versus INS in patients with T2D inadequately controlled on metformin with or without sulphonylurea over a long period (52 weeks). The mean total daily insulin dose at week 52 in the current study was 37.9 U, which was lower than that reported in most treat‐to‐target studies where the daily insulin dose varied between 37 and 62 U.[17](#dom13981-bib-0017){ref-type="ref"}, [18](#dom13981-bib-0018){ref-type="ref"}, [19](#dom13981-bib-0019){ref-type="ref"}, [20](#dom13981-bib-0020){ref-type="ref"} Glycaemic endpoint in the INS arm is dependent on the aggressiveness of the insulin dose titration. However, although hypoglycaemia is relatively rare at insulin initiation, it is essential to achieve a balance between a lower glucose level and hypoglycaemic risk. In the current study, a proportion of patients without hypoglycaemia did not achieve target HbA1c levels, indicating that the insulin titrations could have been more aggressive. However, daytime glucose control was crucial, as approximately 50% of patients receiving insulin had hypoglycaemia, which would probably have become pronounced with a more aggressive titration schedule. FDCs with different classes of glucose‐lowering agents are advantageous over monotherapies, as they enhance adherence to therapy and reduce treatment burden, improve glycaemic control, increase patient satisfaction and lower healthcare costs.[21](#dom13981-bib-0021){ref-type="ref"}, [22](#dom13981-bib-0022){ref-type="ref"} An FDC therapy with DAPA + SAXA differs from the other classes of antihyperglycaemic drugs by its complementary mechanism of action, low risk for hypoglycaemia without increasing the risk of BW gain,[10](#dom13981-bib-0010){ref-type="ref"}, [23](#dom13981-bib-0023){ref-type="ref"}, [24](#dom13981-bib-0024){ref-type="ref"} and no requirement for dose titration, which simplifies the therapy compared with insulin. Results of our short‐term trial showed that oral combination therapy with DAPA 10 mg and SAXA 5 mg resulted in non‐inferior reductions in HbA1c, with a beneficial BW profile and a lower prevalence of hypoglycaemia versus insulin, regardless of the presence or absence of background sulphonylurea.[14](#dom13981-bib-0014){ref-type="ref"} The current extension study demonstrated the sustained efficacy of oral combination therapy with DAPA + SAXA as add‐on to metformin with or without sulphonylurea over 52 weeks in reducing HbA1c and BW from baseline, with a lower prevalence of hypoglycaemia versus INS. These results were consistent with those of a previous 52‐week study comparing DAPA with sulphonylureas as add‐ons to metformin therapy; hypoglycaemic events with DAPA were significantly lower versus sulphonylureas.[25](#dom13981-bib-0025){ref-type="ref"}

The clinically relevant and sustained change in BW from baseline to week 52 in the DAPA + SAXA group, which was significantly greater compared with the INS group, supports results from previous studies showing that treatment with DAPA alone or in combination with SAXA was associated with BW reduction, whereas insulin treatment was associated with BW gain.[10](#dom13981-bib-0010){ref-type="ref"}, [23](#dom13981-bib-0023){ref-type="ref"}, [26](#dom13981-bib-0026){ref-type="ref"} The higher proportion of patients achieving optimal glycaemic control after 52 weeks with a lower incidence of hypoglycaemia in the DAPA + SAXA group compared with those receiving INS corroborates previous evidence.[27](#dom13981-bib-0027){ref-type="ref"}, [28](#dom13981-bib-0028){ref-type="ref"}, [29](#dom13981-bib-0029){ref-type="ref"} However, evidence is lacking regarding the effect of these drugs alone compared with insulin in achieving optimal glycaemic control without hypoglycaemia or BW gain. More patients required rescue medication in the INS group than the DAPA + SAXA group.

Overall, AEs and SAEs were balanced between the two groups. The safety and tolerability profile of DAPA + SAXA was consistent with that of the individual agents, supporting observations from previous studies.[5](#dom13981-bib-0005){ref-type="ref"}, [10](#dom13981-bib-0010){ref-type="ref"}, [12](#dom13981-bib-0012){ref-type="ref"}, [30](#dom13981-bib-0030){ref-type="ref"}, [31](#dom13981-bib-0031){ref-type="ref"} Oral administration of glucose‐lowering drugs is often preferred to injections by both patients and healthcare professionals.[32](#dom13981-bib-0032){ref-type="ref"} A treatment strategy including oral, insulin‐independent, glucose‐lowering drugs instead of injectable basal insulin in patients with uncontrolled T2D is a welcome alternative. The function of DPP‐4is with sulphonylurea mechanistically relies on residual β‐cell activity, while SGLT‐2is work complementarily to DPP4is, reducing hyperglycaemia through renal excretion of glucose, independent of insulin secretion, thus reducing glucotoxicity[33](#dom13981-bib-0033){ref-type="ref"} and β‐cell burden. The risk of genital infections with combination therapy is lower than that observed with DAPA alone, which is suggestive of a protective effect.[13](#dom13981-bib-0013){ref-type="ref"}, [34](#dom13981-bib-0034){ref-type="ref"}, [35](#dom13981-bib-0035){ref-type="ref"}

An important strength of this study is its randomized and multinational design. Most patients who entered the long‐term extension completed the study. These results are particularly promising because patients included in the study had high baseline HbA1c levels. Hence, the oral treatment combination of DAPA + SAXA is an efficient and valid alternative to insulin for patients with high glucose levels. However, a limitation is that the study was not blinded, although both patient groups received active treatment. Furthermore, although DAPA + SAXA showed durability up to 52 weeks when added to metformin with or without sulphonylurea, durability beyond 1 year with this combination remains to be determined.

In conclusion, the present study showed that administration of an oral combination therapy of DAPA + SAXA allowed patients with T2D to achieve better glycaemic control compared with INS over a long period. DAPA + SAXA prevented BW gain and lowered the risk of hypoglycaemia. Previous studies have shown an association between lower hypoglycaemia, reduced risk of cardiovascular disease and cognitive impairment, and better quality of life.[36](#dom13981-bib-0036){ref-type="ref"}, [37](#dom13981-bib-0037){ref-type="ref"} SGLT2is are associated with a beneficial cardiovascular profile.[38](#dom13981-bib-0038){ref-type="ref"}, [39](#dom13981-bib-0039){ref-type="ref"} Therefore, compared with insulin, the combination therapy of DAPA + SAXA as an add‐on to metformin with or without sulphonylurea is a viable long‐term treatment option for patients with T2D because of easier administration, lower healthcare resource utilization and a beneficial metabolic profile.
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